Unternehmen wird geladen
Keep exploring
The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T $A+
JNJJohnson & Johnson688,6B $A+
MRKMerck & Co., Inc.364,3B $A
NVSNovartis AG306,3B $A
AMGNAmgen Inc.251,9B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Womit das Unternehmen Geld verdient
- Sales of prescription medicines for diabetes, obesity and other conditions
Konkurriert mit
Was es verkauft3
Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.
Wer es kauft3
- People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
- Pharmacies and telehealth providers that supply medicines to patients.
- Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
- 2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
- 3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.
Was schiefgehen könnte
- 1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
- 2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
- 3Cybersecurity breaches could disrupt the business.
Über Novo Nordisk A/S
Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.
- Hauptsitz
- Bagsværd, Denmark
- Gegründet
- 1923
- Beschäftigte
- around 66,700 (Q2 2026, medium)
- Notiert an
- New York Stock Exchange
- Geschäftsjahresende
- December 31
Gebaut aus den eigenen Einreichungen von Novo Nordisk A/S bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dieses Unternehmen berichtet in DKK. Die Zahlen werden zu 1,00 $ = 6,7640 DKK, dem aktuellen Kurs, in US-Dollar umgerechnet und auf alle Perioden gleich angewandt — so gehören Wachstum und Margen dem Unternehmen und nicht dem Wechselkurs. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
